News articles about CVS Health (NYSE:CVS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. CVS Health earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media headlines about the pharmacy operator an impact score of 46.2954929363446 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- CVS Health (CVS) Upgraded to “Overweight” by Morgan Stanley (americanbankingnews.com)
- CVS Health (NYSE:CVS) Stock Rating Reaffirmed by Tigress Financial (nismagazine.com)
- CVS, Walgreens Say Drug Prices Are Easing After Years of Ballooning — Update (foxbusiness.com)
- McKesson Completes Acquisition Of RxCrossroads From CVS Health For $735 Million (benzinga.com)
- CVS Health Breaks Above 200-Day Moving Average – Bullish for CVS (nasdaq.com)
Several brokerages have issued reports on CVS. Royal Bank of Canada began coverage on CVS Health in a report on Tuesday, September 19th. They set an “outperform” rating and a $95.00 price target for the company. Jefferies Group raised their price target on CVS Health from $82.00 to $86.00 and gave the company a “hold” rating in a report on Friday, September 15th. ValuEngine downgraded CVS Health from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Robert W. Baird reaffirmed a “hold” rating and set a $77.00 price target on shares of CVS Health in a report on Friday, October 27th. Finally, Mizuho set a $90.00 price target on CVS Health and gave the company a “buy” rating in a report on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. CVS Health currently has an average rating of “Buy” and a consensus target price of $86.42.
CVS Health (NYSE:CVS) last posted its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.01. The firm had revenue of $46.18 billion for the quarter, compared to analysts’ expectations of $46.17 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.64 EPS. equities research analysts expect that CVS Health will post 5.9 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.55%. The ex-dividend date of this dividend is Tuesday, January 23rd. CVS Health’s payout ratio is 41.32%.
In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the transaction, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.61% of the stock is owned by company insiders.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.